Last reviewed · How we verify
Oxycodone Naltrexone (a)
Oxycodone naltrexone is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naltrexone) designed to provide analgesia while reducing opioid-related adverse effects and abuse potential.
Oxycodone naltrexone is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naltrexone) designed to provide analgesia while reducing opioid-related adverse effects and abuse potential. Used for Moderate to severe chronic pain.
At a glance
| Generic name | Oxycodone Naltrexone (a) |
|---|---|
| Sponsor | Elite Laboratories, Inc |
| Drug class | Opioid agonist-antagonist combination |
| Target | Mu-opioid receptor (oxycodone agonist); opioid receptors (naltrexone antagonist) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Oxycodone binds to mu-opioid receptors to produce analgesia and pain relief. Naltrexone, an opioid antagonist, is included in the formulation to block some opioid effects and theoretically reduce constipation, respiratory depression, and abuse liability. The combination aims to maintain analgesic efficacy while mitigating common opioid side effects.
Approved indications
- Moderate to severe chronic pain
Common side effects
- Nausea
- Constipation
- Dizziness
- Drowsiness
- Headache
Key clinical trials
- Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) (PHASE1)
- Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) (PHASE1)
- Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101) (PHASE1)
- Evaluation of Oral PF614 Relative to OxyContin (PF614-102) (PHASE1)
- A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers (PHASE1)
- A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
- Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone (PHASE1)
- Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxycodone Naltrexone (a) CI brief — competitive landscape report
- Oxycodone Naltrexone (a) updates RSS · CI watch RSS
- Elite Laboratories, Inc portfolio CI